Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSD
Dates
study started
completion around
Principal Investigator
by Saima Aslam, MD (ucsd)

Description

Summary

This study is being done to find out the best time to start medication for Hepatitis C Virus (HCV) in HCV-negative recipients of HCV-positive (HCV D+/R-) kidney transplants. Participants will be randomized into one of two groups:

Arm 1 - Prophylaxis: This group will start the HCV medication before transplant and will take a shorter course of HCV medication for 2 weeks.

Arm 2 - Transmit and Treat: This group will start the HCV medication after transplant and will take the full course (12 weeks) of HCV medication.

Official Title

Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From Hepatitis C Virus-Infected Donors to Uninfected Recipients: a Randomized Controlled Trial

Details

Keywords

HCV, Prophylaxis (P2W), Transmit and Treat (T&T)

Eligibility

Locations

  • University of California San Diego accepting new patients
    La Jolla California 92037 United States
  • University of Utah Medical Center accepting new patients
    Salt Lake City Utah 84132 United States

Lead Scientist at University of California Health

  • Saima Aslam, MD (ucsd)
    Clinical Professor, Medicine, Vc-health Sciences-schools. Authored (or co-authored) 106 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Johns Hopkins University
ID
NCT05653232
Study Type
Interventional
Participants
Expecting 120 study participants
Last Updated